Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of subcutaneous versus intravenous toripalimab with standard chemotherapy in first-line recurrent or metastatic non-squamous NSCLC
ChiCTR2400084442Phase 3Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoints: Measured trough concentration at the end of cycle 1 and Area under the concentration-time curve from day 0 to day 21 in cycle 1. Planned start May 2024; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2400084442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084442.